Cargando…
The fate of chemoresistance in triple negative breast cancer (TNBC)
BACKGROUND: Treatment options for women presenting with triple negative breast cancer (TNBC) are limited due to the lack of a therapeutic target and as a result, are managed with standard chemotherapy such as paclitaxel (Taxol®). Following chemotherapy, the ideal tumour response is apoptotic cell de...
Autores principales: | O’Reilly, Elma A., Gubbins, Luke, Sharma, Shiva, Tully, Riona, Guang, Matthew Ho Zhing, Weiner-Gorzel, Karolina, McCaffrey, John, Harrison, Michele, Furlong, Fiona, Kell, Malcolm, McCann, Amanda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4661576/ https://www.ncbi.nlm.nih.gov/pubmed/26676166 http://dx.doi.org/10.1016/j.bbacli.2015.03.003 |
Ejemplares similares
-
The potential role of cofilin-1 in promoting triple negative breast cancer (TNBC) metastasis via the extracellular vesicles (EVs)
por: Howard, Jane, et al.
Publicado: (2021) -
Overexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells
por: Weiner-Gorzel, Karolina, et al.
Publicado: (2015) -
HDAC6 Degradation Inhibits the Growth of High-Grade Serous Ovarian Cancer Cells
por: Ali, Ahlam, et al.
Publicado: (2020) -
Collagen prolyl 4-hydroxylase 1 is essential for HIF-1α stabilization and TNBC chemoresistance
por: Xiong, Gaofeng, et al.
Publicado: (2018) -
Protein and chemotherapy profiling of extracellular vesicles harvested from therapeutic induced senescent triple negative breast cancer cells
por: Kavanagh, E L, et al.
Publicado: (2017)